度普利尤单抗治疗特应性皮炎患者的治疗结局:RELIEVE-AD 研究 1 年结果
RELIEVE-AD 队列研究通过在线调查评估美国中度至重度特应性皮炎成人患者启动度普利尤单抗后 1 年内的自报疾病控制与生活质量。共 699 例患者纳入,632 例和 483 例分别完成第 1 个月和第 12 个月调查。结果显示疾病控制、治疗满意度、 flares、瘙痒、皮肤症状、睡眠、生活质量和日常活动均较基线显著改善,且结果在观测数据和插补数据中一致。
要点
- 第 12 个月时 77.4%(374/483)患者达到充分疾病控制,基线为 5.3%(41/699)。
- 第 12 个月外用和系统性糖皮质激素使用分别降至 40.4% 和 6.2%,基线分别为 68.1% 和 34.9%。
- 治疗满意度从基线 17.7% 升至第 12 个月 85.1%,所有患者自报结局均较基线显著改善。
核心结论
- 与临床试验的患者自报结局一致,本队列研究发现度普利尤单抗治疗与快速且持续达 12 个月的疾病控制相关,所有患者自报结局(包括治疗满意度)相对基线均有统计学显著改善。
研究设计与样本
- 本队列研究使用在线调查,在度普利尤单抗启动前(基线)及启动后 1、2、3、6、9、12 个月进行,纳入通过美国患者支持项目启动度普利尤单抗并同意参与研究的中度至重度特应性皮炎成人患者。
- 数据收集时间为 2018 年 1 月至 2020 年 1 月,分析于 2020 年 5 月完成。
- 共 699 例患者启动度普利尤单抗(431 例 [61.7%] 女性,515 例 [73.7%] 白人),632 例和 483 例分别完成第 1 个月和第 12 个月调查。
主要发现
- 观测数据显示,第 1 个月时 60.9%(385/632)患者达到充分疾病控制(ADCT 总分),第 12 个月时 77.4%(374/483)达到充分疾病控制,基线为 5.3%(41/699),两个时间点与基线比较均 P < .001。
- 第 12 个月时外用糖皮质激素使用率为 40.4%(195/483),基线为 68.1%(476/699);系统性糖皮质激素使用率为 6.2%(30/483),基线为 34.9%(244/699),与基线比较均 P < .001。
- 治疗满意度在基线上为 17.7%(120/699),第 12 个月升至 85.1%(411/483)(P < .001)。
- 各随访时间点患者报告 flares、瘙痒、皮肤症状(皮肤疼痛/酸痛、灼热/烧灼感、触痛)较基线减少,睡眠、健康相关生活质量和日常活动较基线改善。
- 基于观测数据和使用模式混合模型对缺失数据进行插补的结果一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical trial populations may not reflect clinical practice: knowledge generated in other settings can inform clinical decision-making. OBJECTIVE: To evaluate self-reported disease control and quality of life after initiating dupilumab treatment in patients with atopic dermatitis (AD) in the the clinical setting. DESIGN, SETTING, AND PARTICIPANTS: This cohort study using an online survey administered prior to (baseline) and at 1, 2, 3, 6, 9, and 12 months after dupilumab initiation included adults with moderate-to-severe AD who initiated treatment with dupilumab through the US patient support program and agreed to participate in the study. Data were collected between January 2018 and January 2020 and the analysis was completed in May 2020. INTERVENTIONS: Clinically driven treatment with dupilumab. MAIN OUTCOMES AND MEASURES: Disease control measured by the Atopic Dermatitis Control Tool (ADCT); concomitant AD therapies; satisfaction with therapy; skin symptoms (skin pain/soreness, hot/burning feeling, sensitivity to touch) assessed using numerical rating scales; flares; health-related quality of life assessed using the Dermatology Life Quality Index; sleep problems assessed using the ADCT item and a stand-alone question; and the AD-specific Work Productivity and Activity Impairment Questionnaire. RESULTS: Of 699 patients who initiated dupilumab (431 [61.7%] female, 515 [73.7%] White), 632 and 483 completed the survey at months 1 and 12, respectively. As-observed results showed that most patients achieved adequate disease control (ADCT total score) at month 1 with further improvement at month 12 (385 of 632 patients [60.9%] and 374 of 483 [77.4%] for the 2 time points, respectively, vs 41 of 699 [5.3%] at baseline; both P < .001). Use of other AD therapies was reduced at each follow-up vs baseline, including topical and systemic corticosteroids, which were reduced at month 12 to 40.4% (195 of 483 patients) and 6.2% (30 of 483 patients), respectively, from 68.1% (476 of 699) and 34.9% (244 of 699), respectively, at baseline (both P < .001 vs baseline). Patient satisfaction with AD treatment was higher than baseline (120 of 699 [17.7%]) at each follow-up to 85.1% (411 of 483) at month 12 (P < .001). At each follow-up, patients reported reductions in flares, itch, skin symptoms, and improved sleep, health-related quality of life, and daily activities vs baseline. Results were consistent based on observed data and imputed data using pattern mixture models for missing data. CONCLUSIONS AND RELEVANCE: Consistent with patient-reported outcomes in clinical trials, this cohort study found that dupilumab treatment was associated with rapid and sustained disease control for up to 12 months as demonstrated by statistically significant improvements relative to baseline on all patient-reported outcomes including treatment satisfaction.
引用
- Strober B, Mallya UG, Yang M, et al. Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study. JAMA Dermatol. 2022. PMID: 34910086. doi:10.1001/jamadermatol.2021.4778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。